In:
Epilepsia, Wiley, Vol. 41, No. s1 ( 2000-01), p. 72-76
Abstract:
Purpose : A total of 292 adult patients (mean age, 33 years) with partial and/or generalized seizures previously resistant to antiepileptic drug (AED) therapy (median baseline seizure rate, 12 seizures/month) were treated with open‐label topiramate (TPM) in dosages of 100–1,600 mg/day. Methods : The mean duration of TPM treatment was 413 days (range, 84–804 days), and the mean TPM dosage was 503 mg/day (range, 100–1,600 mg/day; median TPM dosage, 300 mg/day). Seizure reduction was calculated from seizure counts during the last 3 months and last 6 months of TPM therapy compared with baseline. Results : Overall, 〉 50% of patients achieved ges;50% seizure reduction. More important, 11 % of patients were seizure‐free for ges;3 months at the last visit; 10% of patients were seizure free for ges;6 months at the last visit. This robust therapeutic response was consistent for patients receiving TPM dosages 〉 400 and 〈 400 mg/day. The most commonly reported adverse events were related to the central nervous system. Over the 2·2‐year treatment period, 19% of patients discontinued TPM therapy because of inadequate seizure control; 32% discontinued because of adverse events. Findings from this study show that TPM is a useful agent for long‐term seizure control, with some patients becoming seizure free for extended periods despite failing previous AED therapy.
Type of Medium:
Online Resource
ISSN:
0013-9580
,
1528-1167
DOI:
10.1111/epi.2000.41.issue-s1
DOI:
10.1111/j.1528-1157.2000.tb02176.x
Language:
English
Publisher:
Wiley
Publication Date:
2000
detail.hit.zdb_id:
2002194-X
Permalink
